Shares of Odonate Therapeutics Inc (NASDAQ:ODT) have been given an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Analysts have set a one year consensus price target of $45.00 for the company and are expecting that the company will post ($1.07) EPS for the current quarter, according to Zacks. Zacks has also given Odonate Therapeutics an industry rank of 89 out of 256 based on the ratings given to related companies.
ODT has been the topic of several recent research reports. Cowen reiterated a “buy” rating on shares of Odonate Therapeutics in a report on Monday, June 3rd. Zacks Investment Research upgraded Odonate Therapeutics from a “sell” rating to a “hold” rating in a report on Friday. Finally, ValuEngine lowered Odonate Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, April 18th.
In related news, CEO Kevin C. Tang acquired 93,692 shares of the stock in a transaction dated Wednesday, June 5th. The stock was purchased at an average cost of $24.92 per share, with a total value of $2,334,804.64. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin C. Tang acquired 76,308 shares of the stock in a transaction dated Friday, June 7th. The stock was bought at an average cost of $27.36 per share, with a total value of $2,087,786.88. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 1,393,077 shares of company stock worth $36,230,094. Corporate insiders own 59.30% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. Tang Capital Management LLC raised its stake in Odonate Therapeutics by 7.6% during the 2nd quarter. Tang Capital Management LLC now owns 14,075,269 shares of the company’s stock valued at $516,422,000 after buying an additional 989,231 shares during the last quarter. Boxer Capital LLC lifted its position in shares of Odonate Therapeutics by 12.9% during the second quarter. Boxer Capital LLC now owns 3,363,377 shares of the company’s stock worth $123,402,000 after purchasing an additional 384,615 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Odonate Therapeutics by 2.6% during the second quarter. Janus Henderson Group PLC now owns 1,315,426 shares of the company’s stock worth $48,262,000 after purchasing an additional 33,325 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Odonate Therapeutics by 182.0% during the second quarter. Price T Rowe Associates Inc. MD now owns 1,042,446 shares of the company’s stock worth $38,247,000 after purchasing an additional 672,721 shares in the last quarter. Finally, Samsara BioCapital LLC lifted its position in shares of Odonate Therapeutics by 3.4% during the second quarter. Samsara BioCapital LLC now owns 615,850 shares of the company’s stock worth $22,596,000 after purchasing an additional 20,000 shares in the last quarter. 77.79% of the stock is owned by hedge funds and other institutional investors.
Shares of Odonate Therapeutics stock traded down $1.09 on Friday, hitting $32.35. 58,341 shares of the company’s stock traded hands, compared to its average volume of 86,307. Odonate Therapeutics has a one year low of $11.54 and a one year high of $43.75. The company has a fifty day moving average of $36.78 and a two-hundred day moving average of $25.36. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of -8.89 and a beta of 1.69.
Odonate Therapeutics (NASDAQ:ODT) last announced its quarterly earnings results on Wednesday, July 24th. The company reported ($1.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.24) by $0.09. As a group, analysts expect that Odonate Therapeutics will post -4.62 EPS for the current year.
About Odonate Therapeutics
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Featured Article: Correction
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.